Table 3.
One-Year Outcomes, by Anticoagulant Class at Outcome (N = 3,048; 2,641 Person-Years)
| Outcome | VKA, No. (%) (n = 1,932) | DOAC, No. (%) (n = 1,116) | Total, No. (%) (N = 3,048) | HR (95% CI) |
|---|---|---|---|---|
| ≥1 arterial or venous event | 26 (1.6) | 16 (1.8) | 42 (1.7) | 0.89 (0.48-1.66) |
| Any bleeding | 83 (5.2) | 68 (7.6) | 151 (6.1) | 0.67 (0.49-0.92) |
| Major bleeding | 27 (1.7) | 20 (2.2) | 47 (1.9) | 0.75 (0.42-1.33) |
| Nonmajor but clinically relevant bleeding | 40 (2.5) | 30 (3.3) | 70 (2.8) | 0.74 (0.46-1.18) |
| Minor bleeding | 16 (1.0) | 18 (2.0) | 34 (1.3) | 0.49 (0.25-0.96) |
| All-cause death | 85 (5.2) | 20 (2.2) | 105 (4.1) | 2.37 (1.45-3.85) |
DOAC = direct oral anticoagulant; HR = hazard ratio; VKA = vitamin K antagonist.